We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ultrasis | LSE:ULT | London | Ordinary Share | GB0001494979 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.095 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMULT
RNS Number : 6679Y
Ultrasis PLC
03 December 2014
Ultrasis plc
("Ultrasis" or the "Company")
Update on financial position
Further to the announcement made by the Company on 20 October 2014 ("the Announcement"), Mr Paul Bell, a substantial shareholder in the Company, has, with the assistance of his advisors, now carried out further diligence with regard to his consideration of supporting potential funding options for Ultrasis.
Unfortunately, Mr Bell has confirmed to the Company that he is not prepared to participate in any refinancing proposal at this time. Mr Bell has, however, stated that he is willing to continue to support the Company on a limited ad hoc basis to be drawn down under and subject to the existing terms of the facilities he has with the Company (the "Current Facilities"), of which GBP436,000 remains undrawn as at today's date and has today confirmed that he will, upon request for funds, provide additional funding of no less than GBP200,000 under the Current Facilities.
In this instance, and as described in the Announcement, it remains the case that Mr Bell's consent is required in relation to each drawdown under the Current Facilities for the reasons set out in an earlier announcement dated 7 October 2014. Assuming these amounts are drawn down in full, the Board expects to have sufficient working capital for at least the next four weeks. During this period, the Board will pursue all options available to it which may include the disposal of certain assets and operations and/or identifying and securing alternative external investment and/or finance.
If the Company is not able to raise additional funds by early January 2015, then the Board will have to consider whether or not the Company can continue to trade beyond this time.
This announcement does not fall under Rule 2.4 of the Takeover Code as the options currently being pursued by the Board do not include the consideration or solicitation of bids for the listed entity, Ultrasis plc.
For all enquiries relating to Ultrasis please contact:
Ultrasis plc Tel: +44 (0) 20 7535 2050 John Smith, Interim Executive Chairman finnCap Ltd Tel: +44 (0) 20 7220 0500 Geoff Nash/Simon Hicks
Notes to Editors:
Ultrasis is a healthcare company with core expertise in health, psychology, software development and programme management. We deliver a range of healthcare products to the consumer, the NHS, the corporate sector and other healthcare providers in the UK and Internationally. Ultrasis was the first company to offer computerised products based on Cognitive Behavioural Therapy (CBT) and interactive multimedia, and is still the world leader in this field.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCTTBRTMBIMBRI
1 Year Ultrasis Chart |
1 Month Ultrasis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions